# NCT05879978 (NCT05879978)

> A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05879978
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Boehringer Ingelheim
- Conditions: Small Cell Lung Carcinoma (SCLC); Neuroendocrine Neoplasms
- Interventions: Obrixtamig; Ezabenlimab
- Enrollment: 45
- Primary outcome: Occurrence of Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) evaluation period

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05879978